ArticleNature communications2018
IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Combination Effects ofBiology · 2026Article
- Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy.Biomarker research · 2024Review
- Primary immunodeficiency-related genes and varicella-zoster virus reactivation syndrome: a Mendelian randomization study.Frontiers in immunology · 2024Article
- Effects of DietaryAnimals : an open access journal from MDPI · 2023Article
- Treg in inborn errors of immunity: gaps, knowns and future perspectives.Frontiers in immunology · 2023Review
- Retinoic acid signaling acts as a rheostat to balance Treg function.Cellular & molecular immunology · 2022Article
- Role of IL-6 in the commitment of T cell subsets.Cytokine · 2021Review
- Infection-induced inflammation from specific inborn errors of immunity to COVID-19.The FEBS journal · 2021Review
- HIF-2α is indispensable for regulatory T cell function.Nature communications · 2020Article
- Review
- Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade.Cancer immunology, immunotherapy : CII · 2019Article
- Treg-mediated prolonged survival of skin allografts without immunosuppression.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
X-linked lymphoproliferative syndrome type-2 (XLP-2) is a primary immunodeficiency disease attributed to XIAP mutation and is triggered by infection. Here, we show that mouse Xiap
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.